Clinical trial supply has become a distributed logistics problem, not a warehousing one. A Phase III trial can run 40 countries, 300 sites, 4,000 patients — with dose-level lot control, rolling enrolment, protocol amendments mid-trial, and zero tolerance for stock-outs or excursions at site. The networks handling this at scale have moved from ERP + spreadsheets to autonomous orchestration. A global biotech scaling rare-disease therapeutics across 30+ countries and a global pharma CDMO handling multi-country clinical supply both run on Shipsy for exactly this reason.
The finding: trial supply is a real-time orchestration problem
The old model — centrally planned quarterly shipments from depot to site — is breaking under modern trial design. Adaptive protocols, basket and umbrella trials, patient-centric decentralised trials (DCTs), and direct-to-patient (DTP) dosing have made the supply problem continuous. Each site’s demand signal shifts with enrolment, screen-fail, and dosing cadence.
Orchestration infrastructure has to respond in hours, not weeks. Shipsy’s clinical supply deployments treat each site as a demand sensor, each IMP (investigational medicinal product) shipment as a tracked object with temperature and custody history, and each country-level depot as a dispatch engine with per-protocol routing rules.
Why clinical trial supply breaks generic logistics stacks
Three reasons.
Lot-level and protocol-level constraints. A site can accept only specific lots under specific protocol amendments. Mis-shipping a prior-amendment lot triggers a protocol deviation. Generic WMS/TMS stacks don’t encode protocol-version constraints natively.
Cold chain is non-negotiable. Many IMPs — biologics, cell & gene, vaccines — have narrow stability windows. An excursion isn’t a cost event, it’s a trial-integrity event. Custody records must be continuous across air, ground, customs, and site storage.
Customs and import licenses are per-shipment. IMP import licenses, country-specific labelling, and bonded storage requirements vary by market. Documentation has to move with each shipment and align to the clinical protocol approved by local regulators.
What Shipsy does for clinical supply
Four mechanisms anchor Shipsy’s clinical trial supply stack.
Site-level demand sensing. Each trial site registers into the control tower with its protocol version, enrolment status, and dosing schedule. Demand is generated continuously, not on a fixed calendar. Site stock-out risk is scored against upcoming dosing events.
Protocol-aware routing. Shipsy’s control tower enforces lot-to-protocol eligibility at dispatch. An amendment 4 site cannot receive amendment 3 lots unless explicitly approved. This is a database-level constraint, not a checklist.
Continuous cold chain custody via Atlas. Atlas — Shipsy’s autonomous control tower — ingests IoT logger feeds from the shipper, airline milestone data, ground handler status, and site BMS into a single per-shipment custody record. Excursions are scored against the specific IMP’s stability budget, and Astra triggers remediation automatically (see the related pharma cold chain management deep-dive).
Customs and documentation automation. Per-country import license records are attached to each shipment at generation. Customs paperwork, labelling variants, and bonded storage routing are orchestrated from the central control tower. Clara communicates with site coordinators on delivery windows and custody status.
Clinical trial supply control map
| Trial operation concern | Shipsy mechanism | Impact |
|---|---|---|
| Site stock-out risk at dosing event | Continuous demand sensing + auto-replenish | Dosing continuity |
| Wrong-amendment lot delivered to site | Protocol-aware dispatch constraint | Protocol deviation prevention |
| IMP excursion in transit | Atlas custody record + Astra remediation | IMP release integrity |
| Import license per country | Per-shipment license + doc automation | Customs hold reduction |
| Direct-to-patient dosing | Last-mile with identity + cold-kit workflows | Patient-centric dosing support |
What clinical ops leaders should do in the next 90 days
Map your current trial supply pain by failure mode. Most trial logistics teams have a dashboard of excursions, late shipments, and customs holds but rarely a root-cause breakdown. The 80/20 almost always reveals one dominant failure mode per country — addressing it is the first ROI.
Next, evaluate your site demand signal. If sites place IMP orders manually every few weeks, you are running a pull system on latency. Continuous demand sensing from enrolment and dosing data removes that latency.
Finally, pressure-test your cold chain custody chain. Ask: for any IMP shipment, can you produce a single timeline covering shipper, airline, ground, customs, and site BMS temperature plus custody? If the answer requires stitching spreadsheets, your audit readiness is fragile.
For the broader pharma vertical positioning, see how Shipsy fits pharma. For underlying orchestration infrastructure, see Atlas, Shipsy’s autonomous control tower.